Analysis of organ function and comrbidity parameters, as well as established multiple myelom prognosis factors as structured, sysematic aquisition of age-associated concomitant factors and their prognostic relevance for evidence based assertions concerning therapy tolerance and survival in myelom patients.
Recruiting
- Conditions
- C90Multiple myeloma and malignant plasma cell neoplasms
- Registration Number
- DRKS00003868
- Lead Sponsor
- niversitätsklinikum Freiburg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients with newly diagnosed or recurrent requiring therapy for multiple myeloma
Exclusion Criteria
No need of therapy of multiple myeloma
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Detection of comorbidities (MM -specific factors , organ function, function assessment) in patients with multiple myeloma and their influence on the Ereignisfreie- and overall survival.
- Secondary Outcome Measures
Name Time Method 1. Detection of already established comorbidity scores ( HCT -CI , Kaplan- Feinstein ) and compared with a newly developed myeloma- specific score.<br>2.Evaluation a weighted vs. unweighted MM specific comorbidity score.<br>3.Evaluation of comorbidity scores to make a prediction regarding . Therapy tolerability / toxicity of chemotherapy can .<br>4. Influence of therapy concepts retrospectively in the period 1997-2003 compared with new Therapieagentien in time from 2003 to 2009 on the Ereignisfreie- and overall survival in patients with multiple myeloma.<br><br>